| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,908 |
1,551 |
$262K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,262 |
1,165 |
$218K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,852 |
1,384 |
$114K |
| 87581 |
|
1,402 |
1,312 |
$35K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
677 |
478 |
$23K |
| 87631 |
|
225 |
217 |
$14K |
| 87640 |
|
398 |
381 |
$8K |
| 87498 |
|
336 |
326 |
$7K |
| 86684 |
|
336 |
327 |
$6K |
| 86615 |
|
336 |
326 |
$5K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
111 |
107 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
27 |
26 |
$1K |
| 87486 |
|
58 |
54 |
$1K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
16 |
16 |
$311.60 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
101 |
44 |
$262.73 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
20 |
14 |
$29.31 |
| 36415 |
Collection of venous blood by venipuncture |
23 |
14 |
$22.40 |